NCT05067335View on ClinicalTrials.gov

A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

PHASE3CompletedINTERVENTIONAL
Enrollment

327

Participants

Timeline

Start Date

October 21, 2021

Primary Completion Date

November 9, 2023

Study Completion Date

November 9, 2023

Conditions
Osteoporosis
Interventions
DRUG

Romosozumab

Subjects will receive romosozumab in a specified sequence during the treatment Period.

DRUG

Placebo

Subjects will receive Placebo in a specified sequence during the treatment Period.

Trial Locations (30)

Unknown

Op0002 20040, Beijing

Op0002 20115, Beijing

Op0002 20125, Beijing

Op0002 20127, Beijing

Op0002 20128, Beijing

Op0002 20130, Beijing

Op0002 20131, Beijing

Op0002 20157, Beijing

Op0002 20021, Chengdu

Op0002 20133, Chengdu

Op0002 20137, Chengdu

Op0002 20205, Foshan

Op0002 20117, Guangzhou

Op0002 20124, Guangzhou

Op0002 20209, Nanchang

Op0002 20135, Nanjing

Op0002 20202, Pingxiang

Op0002 20199, Rui’an

Op0002 20116, Shanghai

Op0002 20118, Shanghai

Op0002 20121, Shanghai

Op0002 20123, Shanghai

Op0002 20129, Shanghai

Op0002 20119, Suzhou

Op0002 20204, Suzhou

Op0002 20122, Tianjin

Op0002 20136, Tianjin

Op0002 20120, Wuhan

Op0002 20134, Yueyang

Op0002 20132, Zhengzhou

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT05067335 - A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis | Biotech Hunter | Biotech Hunter